Aperture Therapeutics, a biotechnology company pioneering next-generation precision medicines for neurodegenerative diseases, today announced the advancement of its matrix metalloproteinase-9 (MMP9) ...

Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing and Axolabs, part of LGC Group, an oligonucleotide Contract Research ...

Though specific data for bepirovirsen remain under wraps, GSK plans to file for approval in the first quarter of 2026.

GSK’s potential “functional cure” for hepatitis B drug has proven its worth in a pair of hotly anticipated phase 3 studies, ...

UK pharma major GSK today announced positive results from its two pivotal Phase III trials, B-Well 1 [NCT05630807] and B-Well ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive results from two pivotal Phase 3 studies, ...

Their award-winning projects in the prestigious competition cover topics in the sciences, engineering, social sciences and ...

GSK and Ionis report strong Phase 3 results for a hepatitis B drug that improved cure rates and could support regulatory filings in early 2026.

The B-Well 1 and B-Well 2 trials evaluated the safety, efficacy, and durability of bepirovirsen in nucleos(t)ide analogue-treated participants with CHB.

The companies didn’t provide details, but said global regulatory filings are now planned for the therapy, an oligonucleotide ...

How do tertiary lymphoid structures influence immunotherapy outcomes in Merkel cell carcinoma? Spatial proteomics reveals key ...

Investing.com -- GSK plc (LON:GSK) on Wednesday annoucned positive phase III trial results for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B (CHB), meeting primary ...